Companies › Engeneic
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Sep 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| E-EDV-D682 Bacterially derived nanocell (EDV) packaged with chemotherapeutic drug, targeted to cancer | – | Phase 1 | Pancreatic Cancer, Metastatic | Sep 2028 |
| EDV-GC Bacterially derived nanocell (EDV) packaging alpha-galactosyl ceramide (GC) immunomodulato | – | Phase 1 | Pancreatic Cancer, Metastatic | Sep 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07049055 | E-EDV-D682 | Phase 1 | Pancreatic Cancer, Metastatic | Oncology | Sep 2028 |
| NCT07049055 | EDV-GC | Phase 1 | Pancreatic Cancer, Metastatic | Oncology | Sep 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.